Kelun-Biotech surged 6.7% to close at HKD 499 on heavy volume, driven by ASCO data showcasing sac-TMT plus pembrolizumab in first-line PD-L1-positive NSCLC published in The Lancet and Merck advancing 17 trials for its core ADC. The stock staged a V-shaped rebound after slipping to an intraday low of HKD 477.2 in morning trade, reaching HKD 499.6 in late afternoon. Q4 revenue jumped 110% YoY to HKD 615.8M while net loss narrowed 57.1%. Yet shares remain 14.1% below the 52-week high of HKD 581 and trade well above MA20 (415.48) and MA60 (448.9); Goldman Sachs raised its TP to HKD 561.4 with a Buy rating. However, the company still reports negative EPS and a PB of 21.6x, while peer Akeso tumbled 8% today, weighing on sector sentiment.